EE05442B1 - V„ikeses annuses entekaviiri sisaldav ravimkoostis B-hepatiidi viirusinfektsiooni raviks ning meetod selle valmistamiseks - Google Patents

V„ikeses annuses entekaviiri sisaldav ravimkoostis B-hepatiidi viirusinfektsiooni raviks ning meetod selle valmistamiseks

Info

Publication number
EE05442B1
EE05442B1 EEP200200484A EEP200200484A EE05442B1 EE 05442 B1 EE05442 B1 EE 05442B1 EE P200200484 A EEP200200484 A EE P200200484A EE P200200484 A EEP200200484 A EE P200200484A EE 05442 B1 EE05442 B1 EE 05442B1
Authority
EE
Estonia
Prior art keywords
hepatitis
preparation
treatment
pharmaceutical composition
virus infection
Prior art date
Application number
EEP200200484A
Other languages
English (en)
Estonian (et)
Inventor
J. Colonno Richard
L. Sprockel Omar
Harianawala Abizer
S. Desai Divyakant
G. Fakes Michael
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26881354&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE05442(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of EE200200484A publication Critical patent/EE200200484A/xx
Publication of EE05442B1 publication Critical patent/EE05442B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
EEP200200484A 2000-02-29 2001-01-26 V„ikeses annuses entekaviiri sisaldav ravimkoostis B-hepatiidi viirusinfektsiooni raviks ning meetod selle valmistamiseks EE05442B1 (et)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18567200P 2000-02-29 2000-02-29
US22131300P 2000-07-28 2000-07-28
PCT/US2001/002630 WO2001064221A1 (en) 2000-02-29 2001-01-26 Low dose entecavir formulation and use

Publications (2)

Publication Number Publication Date
EE200200484A EE200200484A (et) 2004-04-15
EE05442B1 true EE05442B1 (et) 2011-08-15

Family

ID=26881354

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200200484A EE05442B1 (et) 2000-02-29 2001-01-26 V„ikeses annuses entekaviiri sisaldav ravimkoostis B-hepatiidi viirusinfektsiooni raviks ning meetod selle valmistamiseks

Country Status (35)

Country Link
US (1) US6627224B2 (da)
EP (2) EP1642582A1 (da)
JP (3) JP5140222B2 (da)
KR (1) KR100757155B1 (da)
AR (1) AR027965A1 (da)
AT (1) ATE312613T1 (da)
AU (1) AU2001229775A1 (da)
BG (1) BG65815B1 (da)
BR (1) BRPI0108435B8 (da)
CA (1) CA2401569C (da)
CO (1) CO5261593A1 (da)
CZ (1) CZ303395B6 (da)
DE (1) DE60115870T3 (da)
DK (1) DK1267880T4 (da)
EA (1) EA006181B1 (da)
EE (1) EE05442B1 (da)
EG (1) EG24408A (da)
ES (1) ES2253403T5 (da)
GE (1) GEP20053504B (da)
HK (1) HK1048771A1 (da)
HR (1) HRP20020649A2 (da)
HU (1) HU230698B1 (da)
IL (1) IL150447A0 (da)
MX (1) MXPA02008359A (da)
MY (1) MY127422A (da)
NO (1) NO324014B1 (da)
NZ (1) NZ520024A (da)
PE (1) PE20020770A1 (da)
PL (1) PL201411B1 (da)
RS (1) RS51561B (da)
SI (1) SI1267880T2 (da)
SK (1) SK288008B6 (da)
TW (1) TWI287988B (da)
UA (1) UA84534C2 (da)
WO (1) WO2001064221A1 (da)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ520024A (en) * 2000-02-29 2005-03-24 Bristol Myers Squibb Co Low dose entecavir formulation and usein treating hepatitis B virus infection
TWI275392B (en) * 2002-04-08 2007-03-11 Bristol Myers Squibb Co Low dose liquid entecavir formulations and use
AR040588A1 (es) 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
BRPI0317255B8 (pt) 2002-12-11 2021-05-25 Bristol Myers Squibb Co processo para preparar o agente antiviral [1s-(1alfa, 3alfa, 4beta)]-2-amino-1,9-diidro-9-[4-hidróxi-3-(hidroximetil)-2-metilenociclopentil]-6h-purin-6-ona método de seu isolamento, preparação do éster e respectivos compostos
DE602004014470D1 (de) 2003-01-14 2008-07-31 Gilead Sciences Inc Zusammensetzungen und verfahren zur antiviralen kombinationstherapie
AU2004291149C1 (en) 2003-11-17 2021-01-21 Biomarin Pharmaceutical Inc. Methods and Compositions for the Treatment of Metabolic Disorders
NZ547880A (en) * 2003-11-18 2010-02-26 Boehringer Ingelheim Int Solid pharmaceutical preparation form
US7511139B2 (en) 2004-06-04 2009-03-31 Bristol-Myers Squibb Company Process for the preparation of entecavir and novel intermediates thereof via carbon-silicon oxidation
JP4756153B2 (ja) * 2004-08-27 2011-08-24 富士製薬工業株式会社 低成分含量の錠剤の製造方法
MX2007003519A (es) * 2004-09-23 2007-08-07 Fmc Corp Composicion de recubrimiento.
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
CN101245068A (zh) * 2007-02-14 2008-08-20 浙江医药股份有限公司新昌制药厂 结晶型态的恩替卡韦及其制备方法和其药物组合物及用途
TW200904405A (en) 2007-03-22 2009-02-01 Bristol Myers Squibb Co Pharmaceutical formulations containing an SGLT2 inhibitor
CA2778273A1 (en) 2009-10-28 2011-05-12 Mcneil-Ppc, Inc. Fast dissolving/disintegrating coating compositions
US20120308652A1 (en) * 2009-12-23 2012-12-06 Daniela Stumm Oral form of administration comprising entecavir
DE102009060194A1 (de) 2009-12-23 2011-06-30 ratiopharm GmbH, 89079 Orale Darreichungsform umfassend Entecavir
US9168269B2 (en) 2010-02-18 2015-10-27 The Trustees Of Princeton University Inhibitors of long and very long chain fatty acid metabolism as broad spectrum anti-virals
AR080863A1 (es) 2010-03-31 2012-05-16 Millennium Pharm Inc Derivados del acido1-amino-2-ciclopropiletilboronico, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer.
EP2606895A4 (en) * 2010-10-12 2014-04-02 Univ Wuhan TRANSDERMAL ABSORPTION STAMP OF ANTIVIRAL DRUG AND METHOD FOR PREPARING THE SAME
EP2508172A1 (en) 2011-04-06 2012-10-10 Zentiva, a.s. Stable and uniform formulations of entecavir and preparation method thereof
KR101594820B1 (ko) * 2011-06-16 2016-02-17 건일제약 주식회사 엔테카비르를 함유하는 미립구 및 이의 제조방법
KR101439635B1 (ko) 2011-11-01 2014-09-11 대원제약주식회사 안정성이 향상된 엔테카비어를 함유하는 약학적 조성물 및 그 제조방법
EP2780001A4 (en) * 2011-11-14 2015-10-28 Hetero Research Foundation SOLID ORAL ENTECAVIR COMPOSITIONS WITH FAST RELEASE
EP2644197A1 (en) * 2012-03-26 2013-10-02 Sanovel Ilac Sanayi ve Ticaret A.S. Novel Pharmaceutical Compositions of Entecavir
EP2644196B1 (en) * 2012-03-26 2019-09-18 Arven Ilac Sanayi ve Ticaret A.S. Pharmaceutical compositions of Entecavir
KR101285008B1 (ko) * 2012-04-18 2013-07-10 제일약품주식회사 저용량 엔테카비어의 경구투여 제제의 제조방법
CA2779052A1 (en) * 2012-05-31 2013-11-30 Pharmascience Inc. Pharmaceutical composition of entecavir and process of manufacturing
CN103908436B (zh) * 2012-12-29 2016-02-10 安徽贝克生物制药有限公司 一种速释型恩替卡韦组合物
KR101512895B1 (ko) 2013-08-09 2015-04-16 대화제약 주식회사 엔테카비어를 포함하는 약학적 조성물의 제조방법
JP6582000B2 (ja) * 2014-06-20 2019-09-25 シーティーシー バイオ インコーポレイテッド エンテカビルを有効成分として含む薬学製剤及びこの製造方法
US11273129B2 (en) 2015-09-30 2022-03-15 Daicel Corporation Particle composition for easy-to-use solid preparation and easy-to-use solid preparation including said particle composition
KR20230112817A (ko) 2022-01-21 2023-07-28 한림대학교 산학협력단 피루브산 및 pdk 억제제를 포함하는 뇌질환의 예방 또는 치료용 조성물

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3836618A (en) * 1971-12-23 1974-09-17 American Home Prod Process for the uniform distribution of a drug on a granulated base
US4513008A (en) * 1982-07-30 1985-04-23 The Vinoxen Company, Inc. Virucidal compositions and therapy
US4489026A (en) * 1982-09-07 1984-12-18 The Upjohn Company Process for preparing solid unit dosage forms of ultra-low dose drugs
US4631284A (en) * 1984-11-19 1986-12-23 Mallinckrodt, Inc. Acetaminophen compositions containing low doses of chlorpheniramine maleate, method for preparing same and tablets formed therefrom
US5206244A (en) 1990-10-18 1993-04-27 E. R. Squibb & Sons, Inc. Hydroxymethyl (methylenecyclopentyl) purines and pyrimidines
JPH08208478A (ja) * 1994-10-14 1996-08-13 Japan Energy Corp 抗エイズ薬製剤およびその製造方法
PT929294E (pt) * 1996-04-04 2003-11-28 Felix Specht Processo para a preparacao de sistemas em po fluidos e/ou directamente compressiveis de baixa dosagem
WO1998009964A1 (en) 1996-09-03 1998-03-12 Bristol-Myers Squibb Company IMPROVED PROCESS FOR PREPARING THE ANTIVIRAL AGENT [1S-(1α, 3α, 4β)]-2-AMINO-1,9-DIHYDRO-9-[4-HYDROXY-3-(HYDROXYMETHYL)-2-METHYLENECYCLOPENTYL]-6H-PURIN-6-ONE
ES2579903T3 (es) * 1998-08-10 2016-08-17 Centre National De La Recherche Scientifique (Cnrs) Beta-L-2'-desoxi-nucleósidos para el tratamiento de la hepatitis B
US5997905A (en) * 1998-09-04 1999-12-07 Mcneil-Ppc Preparation of pharmaceutically active particles
GB9820417D0 (en) 1998-09-18 1998-11-11 Glaxo Group Ltd Antiviral combinations
GB9820420D0 (en) 1998-09-18 1998-11-11 Glaxo Group Ltd Antiviral combinations
GB9820416D0 (en) 1998-09-18 1998-11-11 Glaxo Group Ltd Antiviral combinations
US6432966B2 (en) * 1999-10-29 2002-08-13 Smithkline Beecham Corporation Antiviral combinations
NZ520024A (en) * 2000-02-29 2005-03-24 Bristol Myers Squibb Co Low dose entecavir formulation and usein treating hepatitis B virus infection

Also Published As

Publication number Publication date
NO20024099L (no) 2002-08-28
BR0108435A (pt) 2004-06-15
HUP0500558A2 (hu) 2005-09-28
EP1267880B1 (en) 2005-12-14
MXPA02008359A (es) 2003-02-12
HRP20020649A2 (en) 2004-12-31
DE60115870D1 (de) 2006-01-19
AR027965A1 (es) 2003-04-16
PE20020770A1 (es) 2002-09-06
YU63002A (sh) 2005-03-15
PL201411B1 (pl) 2009-04-30
JP2012255017A (ja) 2012-12-27
PL366102A1 (en) 2005-01-24
DE60115870T3 (de) 2010-07-29
SK11652002A3 (sk) 2003-09-11
GEP20053504B (en) 2005-05-10
HU230698B1 (hu) 2017-09-28
SI1267880T2 (sl) 2010-04-30
NO20024099D0 (no) 2002-08-28
SI1267880T1 (sl) 2006-06-30
JP2004503467A (ja) 2004-02-05
EP1267880B2 (en) 2010-01-20
JP2015178523A (ja) 2015-10-08
TWI287988B (en) 2007-10-11
BRPI0108435B1 (pt) 2019-02-05
EA006181B1 (ru) 2005-10-27
EP1642582A1 (en) 2006-04-05
KR100757155B1 (ko) 2007-09-07
UA84534C2 (uk) 2008-11-10
SK288008B6 (sk) 2012-10-02
CO5261593A1 (es) 2003-03-31
CZ303395B6 (cs) 2012-08-29
EE200200484A (et) 2004-04-15
HUP0500558A3 (en) 2012-08-28
ATE312613T1 (de) 2005-12-15
AU2001229775A1 (en) 2001-09-12
DK1267880T4 (da) 2010-05-17
EP1267880A1 (en) 2003-01-02
US6627224B2 (en) 2003-09-30
US20010033864A1 (en) 2001-10-25
HK1048771A1 (zh) 2003-04-17
RS51561B (sr) 2011-08-31
DK1267880T3 (da) 2006-03-06
JP5921746B2 (ja) 2016-05-24
EG24408A (en) 2009-05-20
BRPI0108435B8 (pt) 2021-05-25
CA2401569A1 (en) 2001-09-07
DE60115870T2 (de) 2006-08-17
EA200200812A1 (ru) 2003-12-25
KR20020082230A (ko) 2002-10-30
WO2001064221A1 (en) 2001-09-07
MY127422A (en) 2006-11-30
NZ520024A (en) 2005-03-24
ES2253403T5 (es) 2010-04-22
BG106905A (bg) 2003-04-30
IL150447A0 (en) 2002-12-01
BG65815B1 (bg) 2010-01-29
ES2253403T3 (es) 2006-06-01
NO324014B1 (no) 2007-07-30
JP5140222B2 (ja) 2013-02-06
CA2401569C (en) 2009-08-18

Similar Documents

Publication Publication Date Title
EE05442B1 (et) V„ikeses annuses entekaviiri sisaldav ravimkoostis B-hepatiidi viirusinfektsiooni raviks ning meetod selle valmistamiseks
IL215891A (en) Hepatitis C Serine Protease Inhibitors, Pharmaceutical Compounds Containing Them, and Their Use in Preparing Drugs to Treat Hepatitis C Infections
TR200402565T4 (tr) Hepatit delta virüsü enfeksiyonunun tedavi edilmesinde ß-L-2'-deoksi-nükleosidlerin kullanımı
AP2002002704A0 (en) Methods and compositions for treating hepatitis c virus
WO2003051306A3 (en) N4-acylcytosine-1,3-dioxolane nucleosides for treatment of viral infections
GB2355932B (en) A pharmaceutical formulation suitable for the treatment of hepatitis B, hepatitis C and other viral infections of the liver and a process for its preparation
IL162236A0 (en) Purified hepatitis c virus envelopeproteins for dagnostic and therapeutic use
AU2002346686A1 (en) Compositions and method for treating hepatitis virus infection
DK1284720T3 (da) L-FMAU til behandling af hepatitis delta-virusinfektion
HK1062579A1 (en) A fusion protein for treatment of hepatitis b virus and its use thereof
AU2002219881A1 (en) Methods and compositions for the treatment of human immunodeficiency virus infection
AU2001246331A1 (en) Hepatitis b virus (hbv) antigenic polypeptide-heat shock protein complex and use thereof
EP1326625A4 (en) IMMUNOGENIC COMPOSITION OF HEPATITIS C AND METHODS OF USING THE SAME
NO20041855L (no) Fremgangsmate for behandling av hepatitt C-virusinfeksjon ved behandling av feilpasienter
IL161138A0 (en) Treatment of hepatitis b virus infection with human monoclonal antibodies
AU2001269092A1 (en) Inhibitors of hepatitis b virus infection
IL236510A0 (en) Use of one or more HBV antigens for the preparation of oral pharmaceutical preparations for the treatment of a person with active HBV infection or hepatocellular carcinoma
NO20041685L (no) Fremgangsmate for behandling av hepatitt C-virusinfeksjon hos pasienter med manglende behandlingsrespons
AU2001234596A1 (en) Use of castanospermine and substituted-castanospermine compounds for treating hepatitis virus infections
AU2001277055A1 (en) Composition for treatment of and method of monitoring hepatitis c virus using interferon-tau
ATE273012T1 (de) Kombinationen von lamivudin und entecavir für behandlung der hepatitis b virus infektion
IL151033A0 (en) Purified hepatitis c virus envelope proteins for diagnostic and therapeutic use
EE04941B1 (et) Ravimid skisofreenia ennetamiseks ja raviks ning nende valmistamine
DK1180041T3 (da) Vaccine med ISA-virus
MA25509A1 (fr) Composition destinee au traitement de l'hepatite c

Legal Events

Date Code Title Description
GB1A Change in the ownership or in the address of the owner
HE1A Change of address